TRCT
KYMR icon

Tower Research Capital (TRC)’s Kymera Therapeutics KYMR Stock Holding History

Tower Research Capital (TRC)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Sell
2,621
-1,383
-35% -$119K 0.01% 1384
2026
Q1 		$333K Buy
4,004
+2,742
+217% +$217K 0.01% 1220
2025
Q4 		$98.2K Sell
1,262
-931
-42% -$62.9K ﹤0.01% 1960
2025
Q3 		$124K Sell
2,193
-3,232
-60% -$146K ﹤0.01% 1831
2025
Q2 		$237K Buy
5,425
+2,858
+111% +$98.4K 0.01% 1623
2025
Q1 		$70.3K Sell
2,567
-2,245
-47% -$81.8K ﹤0.01% 1984
2024
Q4 		$194K Buy
4,812
+2,350
+95% +$106K ﹤0.01% 1747
2024
Q3 		$117K Sell
2,462
-10,663
-81% -$471K ﹤0.01% 2112
2024
Q2 		$392K Buy
13,125
+12,421
+1,764% +$430K 0.01% 1534
2024
Q1 		$28.3K Sell
704
-2,049
-74% -$73.3K ﹤0.01% 2700
2023
Q4 		$70.1K Sell
2,753
-3,899
-59% -$69.7K ﹤0.01% 2911
2023
Q3 		$92.5K Buy
6,652
+3,753
+129% +$75.5K ﹤0.01% 2039
2023
Q2 		$66.6K Buy
2,899
+1,146
+65% +$32.8K ﹤0.01% 2342
2023
Q1 		$52K Sell
1,753
-3,646
-68% -$118K ﹤0.01% 2455
2022
Q4 		$135K Sell
5,399
-13,223
-71% -$353K 0.01% 1593
2022
Q3 		$405K Buy
18,622
+7,093
+62% +$187K 0.01% 1304
2022
Q2 		$227K Buy
11,529
+8,363
+264% +$195K 0.01% 1671
2022
Q1 		$134K Sell
3,166
-1,450
-31% -$61.2K ﹤0.01% 2006
2021
Q4 		$293K Buy
4,616
+910
+25% +$53K 0.01% 1492
2021
Q3 		$218K Buy
3,706
+1,986
+115% +$115K 0.01% 1738
2021
Q2 		$83K Buy
1,720
+236
+16% +$10.2K ﹤0.01% 2574
2021
Q1 		$58K Buy
1,484
+734
+98% +$44.2K ﹤0.01% 2994
2020
Q4 		$47K Sell
750
-220
-23% -$10.7K ﹤0.01% 3182
2020
Q3 		$31K Buy
+970
New +$29.6K ﹤0.01% 3715

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Tower Research Capital (TRC)'s KYMR Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Kymera Therapeutics (KYMR) stake by 35% in Q2 2026, selling an estimated $119K and leaving 2,621 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #1384.

Tower Research Capital (TRC) first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. The position peaked at $405K in Q3 2022. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Tower Research Capital (TRC) held 2,621 shares of Kymera Therapeutics worth $301K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,383 Kymera Therapeutics shares in Q2 2026, an estimated $119K.
  • Kymera Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1384 holding.
  • Tower Research Capital (TRC) first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Kymera Therapeutics position peaked at $405K in Q3 2022.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.